Buyback yield (TTM)
0.44%
Shareholder yield (TTM)
2.78%
5Y share count change
-2.2%
Buyback spend (TTM)
$793.00M
Cumulative buybacks
$34.08B
Key takeaways
- Abbott Laboratories (ABT) repurchased about $793.00M of stock over the trailing twelve months.
- Diluted share count is down 2.2% over the last ~5 fiscal years — buybacks are net-shrinking the share base.
- TTM buyback ÷ stock-based-comp ratio of 1.15× — repurchases more than cover SBC dilution.
- Cash buyback spend has compounded at +17.2% per year over the latest 5-year window.
- TTM repurchases used about 25% of free cash flow remaining after dividends.
Dividend & buyback yield over time for Abbott Laboratories (ABT)
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Diluted vs basic shares (annual) for Abbott Laboratories (ABT)
Diluted weighted-average shares are the EPS denominator — a falling count means buybacks are outpacing SBC dilution.
Year-over-year change in diluted shares for Abbott Laboratories (ABT)
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Cash buyback spend over time for Abbott Laboratories (ABT)
Latest: $893.00M
Overview
Abbott Laboratories (ABT) most recent annual buyback spend stands at $893.00M (2025) – plunged 31.0% year-over-year.
Across 2020–2025 (5 years), Abbott Laboratories buyback spend produced a CAGR of +17.2% – with mixed annual results across the window.
Between 2022 and 2025, Abbott Laboratories buyback spend plunged 76.5%, falling from $3.79B to $893.00M.
The record annual buyback spend stands at $3.79B, reached in 2022; the historical low of $0.00 was recorded in 1999.
Abbott Laboratories Buyback Spend 2025: $893.00M
Abbott Laboratories buyback spend in 2025 was $893.00M, plunged 31.0% below 2024.
Abbott Laboratories Buyback Spend 2024: $1.29B
2024's buyback spend for Abbott Laboratories came in at $1.29B, grew 5.5% from 2023.
Abbott Laboratories Buyback Spend 2023: $1.23B
Abbott Laboratories posted buyback spend of $1.23B in 2023, plunged 67.7% below 2022.
Abbott Laboratories Buyback Spend 2022: $3.79B
In 2022, Abbott Laboratories reported buyback spend of $3.79B, surged 65.1% from 2021. This figure represents the highest annual value in the available history.
Abbott Laboratories Buyback Spend 2021: $2.30B
Abbott Laboratories buyback spend in 2021 was $2.30B.
See more financial history for Abbott Laboratories (ABT).
Buyback, SBC & dilution history
Buyback spend, SBC, net dilution effect, and share count.
| 2025 | $893.00M | $664.00M | $229.00M | 0.41% | 1.75B | -0.1% | |
| 2024 | $1.29B | $673.00M | $622.00M | 0.66% | 1.75B | -0.1% | |
| 2023 | $1.23B | $644.00M | $583.00M | 0.64% | 1.75B | -0.9% | |
| 2022 | $3.79B | $685.00M | $3.11B | 1.99% | 1.76B | -1.4% | |
| 2021 | $2.30B | $640.00M | $1.66B | 0.93% | 1.79B | +0.2% | |
| 2020 | $403.00M | $546.00M | −$143.00M | 0.21% | 1.79B | +0.3% | |
| 2019 | $718.00M | $519.00M | $199.00M | 0.47% | 1.78B | +0.6% | |
| 2018 | $238.00M | $477.00M | −$239.00M | 0.19% | 1.77B | +1.2% | |
| 2017 | $827.00M | $406.00M | $421.00M | 0.83% | 1.75B | +17.9% | |
| 2016 | $522.00M | $310.00M | $212.00M | 0.92% | 1.48B | -1.5% | |
| 2015 | $2.24B | $292.00M | $1.95B | 3.38% | 1.51B | -1.4% | |
| 2014 | $2.19B | $246.00M | $1.95B | 3.23% | 1.53B | -3.0% | |
| 2013 | $1.60B | $262.00M | $1.34B | 2.70% | 1.57B | -1.1% | |
| 2012 | $2.36B | $433.00M | $1.93B | 4.84% | 1.59B | +1.4% | |
| 2011 | $77.01M | $383.00M | −$305.99M | 0.18% | 1.57B | +0.9% | |
| 2010 | $866.83M | $387.18M | $479.64M | 2.43% | 1.56B | +0.1% | |
| 2009 | $826.35M | $366.36M | $459.99M | 2.07% | 1.55B | -0.4% | |
| 2008 | $1.08B | $347.01M | $734.79M | 2.74% | 1.56B | +0.0% | |
| 2007 | $1.06B | $46.33M | $1.01B | 2.55% | 1.56B | +1.5% | |
| 2006 | $754.50M | $136.47M | $618.03M | 2.10% | 1.54B | -1.8% | |
| 2005 | $1.30B | $9.74M | $1.29B | 4.51% | 1.56B | -0.4% | |
| 2004 | $499.75M | $10.22M | $489.52M | 1.44% | 1.57B | -0.1% | |
| 2003 | $97.62M | $7.66M | $89.96M | 0.30% | 1.57B | -0.1% | |
| 2002 | $0.00 | $11.72M | −$11.72M | — | 1.57B | +0.5% | |
| 2001 | $17.36M | $0.00 | $17.36M | 0.04% | 1.57B | +0.0% | |
| 2000 | $464.86M | $0.00 | $464.86M | — | 1.57B | +0.5% | |
| 1999 | $0.00 | $0.00 | $0.00 | — | 1.56B | -0.2% | |
| 1998 | $876.30M | $0.00 | $876.30M | — | 1.56B | -0.9% | |
| 1997 | $1.05B | $0.00 | $1.05B | — | 1.58B | -0.4% | |
| 1996 | $808.80M | $0.00 | $808.80M | — | 1.58B | — | |
| 1995 | $771.41M | $0.00 | $771.41M | — | — | — | |
| 1994 | $615.95M | $0.00 | $615.95M | — | — | — | |
| 1993 | $465.82M | $0.00 | $465.82M | — | — | — | |
| 1992 | $607.60M | $0.00 | $607.60M | — | — | — | |
| 1991 | $317.80M | $0.00 | $317.80M | — | — | — | |
| 1990 | $605.60M | $0.00 | $605.60M | — | — | — | |
| 1989 | $289.50M | $0.00 | $289.50M | — | — | — |
- 2025$893.00M
- 2024$1.29B
- 2023$1.23B
- 2022$3.79B
- 2021$2.30B
- 2020$403.00M
- 2019$718.00M
- 2018$238.00M
- 2017$827.00M
- 2016$522.00M
- 2015$2.24B
- 2014$2.19B
- 2013$1.60B
- 2012$2.36B
- 2011$77.01M
- 2010$866.83M
- 2009$826.35M
- 2008$1.08B
- 2007$1.06B
- 2006$754.50M
- 2005$1.30B
- 2004$499.75M
- 2003$97.62M
- 2002$0.00
- 2001$17.36M
- 2000$464.86M
- 1999$0.00
- 1998$876.30M
- 1997$1.05B
- 1996$808.80M
- 1995$771.41M
- 1994$615.95M
- 1993$465.82M
- 1992$607.60M
- 1991$317.80M
- 1990$605.60M
- 1989$289.50M
Buybacks vs stock-based compensation for Abbott Laboratories (ABT)
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 1.15×.
Buybacks vs dividends (share of cash returned) for Abbott Laboratories (ABT)
How Abbott Laboratories splits cash returned to shareholders between dividends and buybacks.
Sector peers by buyback spend
Companies in the same sector as Abbott Laboratories, ranked by their latest buyback spend.
| $5.95B | |
| $5.54B | |
| $5.08B | |
| $4.11B | |
| $980.00M | |
| $216.35M | |
| $0.00 | |
| $0.00 |
- $5.95B
- $5.54B
- $5.08B
- $4.11B
- $980.00M
- $216.35M
- $0.00
- $0.00
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $3.19B (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation